Jazz Pharmaceuticals

Jazz hands Chimerix $935M to buy near-approval cancer drug

Jazz drummed up the deal in double time, agreeing to buy Chimerix for $935 million days after its CEO voiced an interest in diversifying the pipeline.

Nick Paul Taylor Mar 5, 2025 8:13am

FDA's principal deputy to depart agency—Chutes & Ladders

Dec 20, 2024 8:30am

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months

Sep 16, 2024 3:00am

Graphic showing arrows missing the bullseye on a target

Jazz's ph. 2 essential tremor test misses endpoint

Jun 20, 2024 9:30am

ASCO: It's back to the basics for cancer drug developers

Jun 5, 2024 10:55am

ASCO: Jazz shares 'unprecedented' biliary tract cancer data

Jun 1, 2024 11:11am